Header

UZH-Logo

Maintenance Infos

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey


Vavricka, Stephan R; Spasojevic, Milos; Rogler, Gerhard; Schoepfer, Alain M; Seibold, Frank; Borovicka, Jan; Frei, Pascal; Zeitz, Jonas; Greuter, Thomas; Manser, Christine; Scharl, Michael; Misselwitz, Benjamin; Straumann, Alex; Michetti, Pierre; Biedermann, Luc; Swiss IBDnet (2017). Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. Digestive Diseases, 35(5):423-432.

Statistics

Citations

Altmetrics

Downloads

8 downloads since deposited on 11 Jan 2018
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2017
Deposited On:11 Jan 2018 07:32
Last Modified:09 Jun 2018 00:00
Publisher:Karger
ISSN:0257-2753
OA Status:Green
Publisher DOI:https://doi.org/10.1159/000475494
PubMed ID:28595194

Download

Download PDF  'Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey'.
Preview
Content: Published Version
Filetype: PDF
Size: 160kB
View at publisher